Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dimetamfetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.64 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.64 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.64 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.64 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.64 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.64 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.64 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.64 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.64 |
| ▸ | MAOB known ✓ | P27338 | 6/20 | 0.61 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 6/20 | 0.60 |
| ▸ | MAOA known ✓ | P21397 | 5/20 | 0.59 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | SNCA | P37840 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimetamfetamine SCHEMBL30559567 | 1.00 | SLC6A4 (0.64) | SLC6A4SLC6A2ADRA2BADRA2CADRA1A | |
| Dimetamfetamine SCHEMBL12203605 | 0.98 | SLC6A4 (0.67) | SLC6A4SLC6A2ADRA2BADRA2CADRA1A | |
| Dimetamfetamine SCHEMBL2110135 | 0.98 | SLC6A4 (0.67) | SLC6A4SLC6A2ADRA2BADRA2CADRA1A | |
| Dimetamfetamine SCHEMBL727641 | 0.98 | SLC6A4 (0.67) | SLC6A4SLC6A2ADRA2BADRA2CADRA1A | |
| Dimetamfetamine SCHEMBL5091346 | 0.95 | SLC6A4 (0.64) | SLC6A4SLC6A2ADRA2BADRA2CADRA1A | |
| Dimetamfetamine SCHEMBL28689942 | 0.95 | SLC6A4 (0.64) | SLC6A4SLC6A2ADRA2BADRA2CADRA1A | |
| Dimetamfetamine SCHEMBL5088134 | 0.95 | SLC6A4 (0.64) | SLC6A4SLC6A2ADRA2BADRA2CADRA1A | |
| Dimetamfetamine SCHEMBL11773332 | 0.95 | SLC6A4 (0.64) | SLC6A4SLC6A2ADRA2BADRA2CADRA1A | |
| SCHEMBL19285766 | 0.88 | MAOB (0.69) | SLC6A4SLC6A2ADRA2BADRA2CADRA1A | |
| Dimetamfetamine SCHEMBL1240177 | 0.85 | SLC6A4 (0.53) | SLC6A4SLC6A2ADRA2BADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| CN-108473484-B | Compounds useful as TRPM8 modulators | 弗门尼舍公司 | 2021-06-29 | — | — | CN | disclosed |
| EP-3356356-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-110479059-A | Trimethylamine exhaust gas recovery system and method in a kind of Parylene production process | JIANGSU NANDA HUAXING SCIENCE AND TECH OF ENVIRONMENTAL PROTECTION CO LTD | 2019-11-22 | — | — | CN | disclosed |
| US-10392371-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190177308-A9 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20180273517-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX INC (US) | 2018-09-27 | — | — | US | disclosed |
| EP-3356356-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | Senomyx, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9732071-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170096418-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED | 2017-04-06 | — | — | US | disclosed |
| US-20170087199-A1 | COMPOSITIONS FOR DELIVERING A COOLING SENSATION | SENOMYX INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | SENOMYX INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-20080214386-A1 | Stability; easily separated from solution; surface treatment of catalyst with Group seven compound; reacting epoxide with carbon dioxide | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-09-04 | — | — | US | disclosed |
| US-5308735-A | Aromatic-aldehyde resins, improved solubility | NIPPON PAINT CO., LTD. (JP) | 1994-05-03 | — | — | US | disclosed |
| EP-0540016-A1 | Photosensitive resin and resin composition for lithographic printing | Nippon Paint Co., Ltd. (JP) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | TAS2R5, TAS1R1, TAS2R1 | SLC6A4 2767/4885SLC6A2 4338/4885ADRA2B 1268/4885 |
| US-10392371-B2 | Compounds useful as modulators of TRPM8 | TRPM8, TRPM4, TRPM6 | SLC6A4 632/4885SLC6A2 1449/4885ADRA2B 1089/4885 |
| US-20190177308-A9 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM6, TRPM4 | SLC6A4 543/4885SLC6A2 1062/4885ADRA2B 1170/4885 |
| US-20180273517-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM6, TRPM4 | SLC6A4 543/4885SLC6A2 1062/4885ADRA2B 1170/4885 |
| US-20170087199-A1 | COMPOSITIONS FOR DELIVERING A COOLING SENSATION | TRPA1, PDE6G, PDE6D | SLC6A4 830/4885SLC6A2 2479/4885ADRA2B 1769/4885 |
| US-20170096418-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM6, TRPM4 | SLC6A4 543/4885SLC6A2 1062/4885ADRA2B 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.